James R. Kasinger - 22 Sep 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: General Counsel and Secretary
Issuer ticker: CRSP
Reported as of: 22 Sep 2026
Net transaction value: -$626,460
SEC form: 4
Accepted by SEC: 24 Sep 2026, 17:35:13 UTC
Prior SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

James R. Kasinger filed Form 4 for CRISPR Therapeutics AG (CRSP) on 24 Sep 2026.

Key facts

This page summarizes James R. Kasinger's Form 4 filing for CRISPR Therapeutics AG (CRSP).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Sep 2026, 17:35.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: -$626,460.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001708172 Primary reporting owner

KASINGER JAMES R.

Relationship: General Counsel and Secretary
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 24 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRSP transaction

Common Shares

Options Exercise

Transaction value
Shares: +10,400
Change %: +11%
Price: $13.62^*
Shares after: 105,184
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F1

CRSP transaction

Common Shares

Sale

Transaction value: $626,460
Shares: -10,400
Change %: -9.9%
Price: $60.24
Shares after: 94,784
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -10,400
Change %: -11%
Price: $0.000000^*
Shares after: 83,232
Date: 22 Sep 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 10,400
Exercise price: $13.62
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.

Footnote F2

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.